Adocia Analysis (April 2026) | Price Target, Growth & Valuation

Adocia

ENXTPA:ADOC

€ 4,64

€0,00 (0,00%)

4,64 €

€0,00 (0,00%)

End-of-day quote: 04/03/2026

Adocia Stock Value

Analysts currently rate Adocia as Buy.

Buy

Adocia Company Info

EPS Growth 5Y

20,52%

Market Cap

€0,09 B

Long-Term Debt

€0,01 B

Annual earnings

N/A

Dividend

€0,00

Dividend Yield

0,00%

Founded

2005

Industry

Health Care

Country

France

Website

Adocia

ISIN Number

FR0011184241

Website

http://www.adocia.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

€14,00

201.72%

Last Update: 04/03/2026

Analysts: 2

Highest Price Target €16,00

Average Price Target €14,00

Lowest Price Target €12,00

In the last five quarters, Adocia’s Price Target has risen from €4,37 to €9,70 - a 121,97% increase. Two analysts predict that Adocia’s share price will increase in the coming year, reaching €14,00. This would represent an increase of 201,72%.

Top growth stocks in the health care sector (5Y.)

What does Adocia do?

Adocia SA (Adocia), a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Business Segments The company concentrates on the development of therapeutic solutions tailored for metabolic diseases, specifically targeting diabetes and obesity. The product pipeline is structured to advance several innovative therapies, each designed to address specific metabolic challe...

Business Segments

The company concentrates on the development of therapeutic solutions tailored for metabolic diseases, specifically targeting diabetes and obesity. The product pipeline is structured to advance several innovative therapies, each designed to address specific metabolic challenges faced by patients.

Business Strategy

Adocia’s business strategy centers on advancing scientific research to deliver innovative solutions for patients suffering from metabolic diseases. The company is committed to the rigorous development of therapies that meet regulatory standards and also demonstrate substantial effectiveness and safety profiles.

The blending of cutting-edge technology with a strong emphasis on research within its specific therapeutic scope allows Adocia to maintain a competitive edge. This involves not just the creation of new therapies but also refining existing solutions to maximize efficacy in patient treatment. By fostering relationships within the medical and research communities, Adocia ensures its pipeline remains relevant and aligned with both scientific advancements and patient needs.

By focusing on strategic partnerships and leveraging intellectual properties, Adocia aims to broaden its market reach while refining its product offerings. Each strategic decision is informed by a deep understanding of patient requirements and the overall healthcare landscape, illustrating the company’s commitment to delivering therapies that can genuinely improve lives.

Products and Services

Adocia focuses on developing innovative therapeutic solutions specifically aimed at metabolic diseases, with significant emphasis on diabetes and obesity. The company has designed tailored therapies that address the unique challenges posed by these conditions. Adocia’s core offerings revolve around biotechnology solutions that harness the potential of its proprietary technologies, aiming to enhance therapeutic benefits for patients.

The lead product candidates target areas, such as insulin delivery mechanisms, where the goal is to improve patient outcomes by optimizing glycemic control. Moreover, the company is working on formulations that allow for improved administration of insulin, aiming to enhance the user experience while ensuring efficient treatment delivery.

In addition to insulin products, Adocia explores partnerships to expand its product portfolio and enhance therapeutic options available in the metabolic disease market. With continuous advancements in research and development, new product candidates are regularly assessed for their potential market impact.

Geographical Markets Served

Adocia primarily operates within the French biotechnology sector, focusing its efforts on the domestic market for its research, development, and commercialization activities.

Customers

Adocia's customer base primarily consists of healthcare providers and medical professionals involved in treating metabolic diseases. The reach extends to various medical practitioners specializing in endocrinology, primary care, and obesity management.

Modes of Sales and Marketing

Adocia employs a multifaceted approach to marketing and distribution channels as part of its broader strategy to reach potential customers. Given the relevance of clinical validation, Adocia prioritizes partnerships and collaborations with leading healthcare professionals and institutions.

History

Adocia SA was founded in 2005. The company was incorporated in 2005.

New support ticket

Explore

Adocia Stock Value

Adocia Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Adocia do?

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Adocia Stock Value

Adocia Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Adocia do?

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.